Mustafa ÇALISİ, Aylin REZVANİ, Alev ÇEVİKOL, SİBEL EYİGÖR

Influence of patient training on persistence, compliance, and tolerability of different dosing frequency regimens of bisphosphonate therapy: An observational study in Turkish patients with

Objective: In our study, we aimed to evaluate the influence of training on compliance and persistencewith bisphosphonate treatment given on a weekly vs. monthly basis in postmenopausal osteoporosispatients.Methods: A total of 979 patients with postmenopausal osteoporosis (mean age: 63.2± 7.2 years) wereincluded in this national, multicenter, prospective non-interventional observational cohort registrystudy. Patients were randomized into training (n¼ 492, 50.3%, mean age: 63.4 ± 7.2 years) and control(n¼ 487, 49.7%, mean age: 63.0 ± 7.1 years) groups. Patients in each intervention group were givenweekly (44.9% and 44.6% for training and control subjects, respectively) or monthly (55.1% and 55.4%,respectively) bisphosphonate regimens. After the initial visit, patients were followed up at three-monthintervals throughout 12 months of treatment for evaluation of persistence, compliance and adverseevents.Results: On average, 79.4% of the patients were persistent with the treatment with a mean of 350.4 daysof duration during the 12-month follow-up period. The mean compliance in the compliant and fullycompliant group remained at an average of 86.6%. No signiŞcant difference was detected between thetraining and control groups in terms of compliance and persistence. SigniŞcantly longer persistence(360.0± 89.0 vs. 345.0 ± 108.0 days; p ¼ 0.035), higher percentage of persistent patients (83.4% vs. 74.2%;p¼ 0.012) and higher compliance rates (88.8% vs. 83.3%; p ¼ 0.002) were noted in monthly regimenpatients in comparison to those given weekly regimen

___

Cramer JA, Lynch NO, Gaudin AF, Walker M, Cowell W. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther. 2006;28:1686e1694.

Moen MD, Keam SJ. Denosumab: a review of its use in the treatment of post- menopausal osteoporosis. Drugs Aging. 2011;28:63e82.

Reginster JY, Rebenda V. Patient preference in the management of post- menopausal osteoporosis with bisphosphonates. Clin Interv Aging. 2006;1: e423.

Hiligsmann M, McGowan B, Bennett K, Barry M, Reginster JY. The clinical and economic burden of poor adherence and persistence with osteoporosis medi- cations in Ireland. Value Health. 2012;15:604e612.

Compston JE, Seeman E. Compliance with osteoporosis therapy is the weakest link. Lancet. 2006;368:973e974.

Cortet B, B enichou O. Adherence, persistence, concordance: do we provide optimal management to our patients with osteoporosis? Joint Bone Spine. ;73:e1ee7. Vytrisalova M, Blazkova S, Palicka V, et al. Self-reported compliance with osteoporosis medication-qualitative aspects and correlates. Maturitas. 2008;60: e229.

Verron E, Bouler JM. Is bisphosphonate therapy compromised by the emergence of adverse bone disorders? Drug Discov Today. 2014;19: e319.

Cott e FE, Mercier F, De Pouvourville G. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis. Clin Ther. 2008;30: e2422.

Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18:1023e1031.

Penning-van Beest FJ, Goettsch WG, Erkens JA. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther. 2006;28:236e242.

Cooper A, Drake J, Brankin E, PERSIST Investigators. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract. 2006;60: e905.

Jans a M, Hern andez C, Vidal M, et al. Multidimensional analysis of treatment adherence in patients with multiple chronic conditions. A cross-sectional study in a tertiary hospital. Patient Educ Couns. 2010;81:161e168.

Shu AD, Stedman MR, Polinski JM, et al. Adherence to osteoporosis medications after patient and physician brief education: post hoc analysis of a randomized controlled trial. Am J Manag Care. 2009;15:417e424.

Guilera M, Fuentes M, Grifols M, Ferrer J, Badia X. OPTIMA study in- vestigators. Does an educational leaflet improve self-reported adherence to therapy in osteoporosis? The OPTIMA study. Osteoporos Int. 2006;17: e671.

Claxton AJ, Cramer J, Pierce C. A systematic review of the associations be- tween dose regimens and medication compliance. Clin Ther. 2001;23: e1310.

Richter A, Anton SE, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther. 2003;25:2307e2335.

Cott e FE, Fautrel B, De Pouvourville GA. Markov model simulation of the impact of treatment persistence in postmenopausal osteoporosis. Med Decis Making. ;29:125e139. Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Meat. 2003;115:209e216.

Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int. 2003;14:259e262.

Nahum R, Hirsch M, Kaplan B. Persistence and compliance with antiresorptive treatment for osteoporosis: the Israeli experience. Maturitas. 2009;63:S24.